Exercise training in pulmonary arterial hypertension associated with connective tissue diseases

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Grünig, Ekkehard ^a   Maier, Felicitas ^a   Ehlken, Nicola ^a   Fischer, Christine ^b   Lichtblau, Mona ^a   Blank, Norbert ^b   Fiehn, Christoph ^c   Stöckl, Frank ^d   Prange, Felix ^a   Staehler, Gerd ^e   Reichenberger, Frank ^f   Tiede, Henning ^f   Halank, Michael ^g   Seyfarth, Hans Jürgen ^h   Wagner, Simone ^a   Nagel, Christian ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c ACURA Centre for Rheumatic Diseases   (Germany)

^d Medical Clinic III   (Germany)

^e Centre for Pulmonary Hypertension   (Germany)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^h UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; EXERCISE; FEMALE; FOLLOW UP; HEART RATE; HUMAN; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; MALE; OVERALL SURVIVAL; OXYGEN CONSUMPTION; OXYGEN SATURATION; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL RATE; WALKING; WORKLOAD;

EID: 84863457725     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3883     Document Type: Article

References (27)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, . ESC Committee for Practice Guidelines (CPG) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-537. ESC Committee for Practice Guidelines (CPG).
2. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62:1088-93. 10.1136/ard.62.11.1088, 1754353, 14583573.
3. Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 1999, 26:1923-29.
4. Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 2006, 25:866-72. 10.1007/s10067-006-0206-5, 16496078.
5. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999, 42:899-909. 10.1002/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L, 10323445.
6. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-30. 10.1164/rccm.200510-1668OC, 16456139.
7. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138:1383-94. 10.1378/chest.10-0260, 20507945.
8. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, . Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012, 71:249-52. 10.1136/annrheumdis-2011-200265, 21998119, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators.
9. Condliffe R, Kiely D, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins D, Hughes RJ, Pepke-Zaba J, Coghlan JG. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179:91-92.
10. Goldberg A. Pulmonary Arterial Hypertension in Connective Tissue Diseases. Cardiol Rev 2010, 18:85-88. 10.1097/CRD.0b013e3181cbcde7, 20160534.
11. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903. 10.1056/NEJMoa012212, 11907289.
12. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, . Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-19. 10.1161/CIRCULATIONAHA.107.742510, 18506008, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group.
13. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006, 114:1482-89. 10.1161/CIRCULATIONAHA.106.618397, 16982941.
14. Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Olschewski H, Halank M. Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration 2011, 81:394-401. 10.1159/000322475, 21311162.
15. Grünig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Sorichter S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R, Nagel C. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J
16. Carvalho MR, Sato EI, Tebexreni AS, Heidecher RT, Schenkman S, Neto TL. Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 53:838-44. 10.1002/art.21605, 16342102.
17. Pinto ALS, Oliveira NC, Gualano B, Christmann RB, Painelli VS, Artioli GG, Prado DM, Lima FR. Efficacy and safety of concurrent training in systemic sclerosis. J Strength Cond Res 2011, 25:1423-28. 10.1519/JSC.0b013e3181d6858b, 21116202.
18. Schouffoer AA, Ninaber MK, Beaart-van de Voorde LJ, van der Giesen FJ, de Jong Z, Stolk J, Voskuyl AE, Scherptong RW, van Laar JM, Schuerwegh AJ, Huizinga TW, Vlieland TP. Randomized comparison of a multidisciplinary team care program with usual care in patients with systemic sclerosis. Arthritis Care Res 2011, 63:909-17.
19. Antonioli CM, Bua G, Frigè A, Prandini K, Radici S, Scarsi M, Danieli E, Malvicini A, Airo P. An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility. Clin Rheumatol 2009, 28:159-65. 10.1007/s10067-008-1006-x, 18795394.
20. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. Thorax 1984, 39:818-22. 10.1136/thx.39.11.818, 459930, 6505988.
21. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982, 14:377-81.
22. Ware J, Sherbourne C. The MOS 36-Item Short-Form Health Survey (SF-36): I. conceptual framework and item selection. Medical Care 1992, 30:473-83. 10.1097/00005650-199206000-00002, 1593914.
23. Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, Riemekasten G, De Vita S, Morganti A, Dölberg M, Berkani O, Guillevin L, . TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008, 67:1222-28. 2564804, 18055477, TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators.
24. Hachulla E, Launay D, Yaici A, Berezne A, de Groote P, Sitbon O, Mouthon L, Guillevin L, Hatron PY, Simonneau G, Clerson P, Humbert M, . French PAH-SSc Network Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology 2010, 49:940-944. 10.1093/rheumatology/kep449, 20144930, French PAH-SSc Network.
25. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122:156-63. 10.1161/CIRCULATIONAHA.109.911818, 20585011.
26. Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011, 20:277-86. 10.1183/09059180.00003811, 22130821.
27. Impens AJ, Wangkaew S, Seibold JR. The 6-minute walk test in scleroderma--how measuring everything measures nothing. Rheumatology 2008, 47:68-69. 10.1093/rheumatology/kem296, 18077492.